Neurofit's Medical AI Analysis Product to Receive 'Japanese Health Insurance Coverage'

Neurofit, an AI solution company specializing in brain disease imaging, announced on the 11th that its imaging analysis software products have been designated as reimbursable under Japan's National Health Insurance. This marks the first case of Neurofit products being covered by health insurance.

Neurofit's video analysis software products 'ScalePet' (left) and 'Aqua'
[Photo by Neurofit]

The approved products are Neurofit Aqua, a brain neurodegeneration imaging analysis software, and Neurofit Scale PET, a positron emission tomography (PET) image quantitative analysis software. These products received medical device certification from Japan's Ministry of Health, Labour and Welfare (MHLW) in 2022, and have now been certified as reimbursable products under Japan's National Health Insurance with additional fees.

Aqua is a software medical device that analyzes abnormal brain atrophy found in magnetic resonance imaging (MRI) of Alzheimer's disease patients. It can analyze brain images regardless of race, age, or gender. Scale PET utilizes PET images to provide quantitative measurements of the deposition levels of amyloid-beta protein, the causative substance of Alzheimer's disease, in detailed brain regions.

Japan operates a health insurance reimbursement system in the form of additional fees, and to promote the medical AI industry, since 2022, it has recognized additional fees for AI software use in medical institutions meeting certain facility conditions through the 'Imaging Diagnosis Management Additional Fee 3' category, which applies to computed tomography (CT) and MRI. Accordingly, qualified Japanese medical institutions can claim additional fees for using AI solutions such as Aqua and Scale PET.

Neurofit expects that this reimbursement approval in Japan will not only significantly increase profitability in the Japanese market but also lead to continuous market expansion. Jin Jun-gil, CEO of Neurofit, said, “This is the first case of our products being covered by insurance reimbursement, and the application of insurance reimbursement to our main products, Aqua and Scale PET, will be an important momentum to increase the proportion of overseas sales.” He added, “We will strengthen cooperation with local partners to actively carry out sales and marketing, and strive to have medical AI solutions covered by insurance in more countries starting with Japan.”

This content was produced with the assistance of AI translation services.